Abstract 1877P
Background
After completion of curative cancer treatment patients enter the re-entry phase, which is characterized by the difficult task to pick up life again. In the re-entry patients face existential concerns, besides physical and psychosocial concerns. Finding meaning and purpose in this new situation may help in dealing with existential concerns. More insight is needed in the existential concerns and the meaning-making process in order to support patients in the re-entry phase.
Methods
We conducted 6 focus groups with 16 patients (5 patients with melanoma and 11 with breast cancer) during the re-entry phase, defined as the point from completion of treatment (after surgical treatment and adjuvant systemic treatment, except for hormonal therapy) up to 18 months in remission. A thematic content analysis was performed by two researchers.
Results
In general, patients experienced existential concerns regarding their worldview, inner posture, values and the future. In addition, patients with melanoma struggled with trust and responsibility for their health; patients with breast cancer struggled with relationships and identity. Outcomes of the meaning-making process identified were: meaning is affected and gives distress, existing sources of meaning are helpful, search for meaning or new meaning has been found. These outcomes were found at the beginning as well as further into the re-entry, however during the re-entry the focus of the meaning-making process shifted from the disease to (picking up) life.
Conclusions
The transition from being a patient to picking up daily life in the re-entry phase involves dealing with existential concerns causing distress. Patients use existing sources of meaning, search for new meaning or have found new meaning in order to deal with these existential concerns and distress. A meaning-centered intervention increasing patients awareness of their personal sources of meaning might strengthen their meaning-making process and can help in dealing with existential concerns.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Visser and L. Post.
Funding
Novartis b.v.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05